Clinical Trial Detail

NCT ID NCT02071927
Title Study of the Glutaminase Inhibitor CB-839 in Leukemia
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Calithera Biosciences, Inc
Indications

acute myeloid leukemia

acute lymphoblastic leukemia

Therapies

Telaglenastat

Age Groups: adult

No variant requirements are available.